Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease
Open accessAbstract
Introduction: Pathologically modified tau protein is the main feature of Alzheimer’s disease (AD) and related tauopathies. Therefore, immunotherapies that target mis-disordered tau represent a promising avenue for the disease-modifying treatment of AD. In this report, we present our discovery of (1) a novel target for tau immunotherapy; (2) monoclonal antibody DC8E8, which neutralizes this target; and (3) the results of efficacy studies of DC8E8 in a murine model of tauopathy. Methods: In vitro tau oligomerisation assays were used for the selection of antibodies. The therapeutic efficacy of DC8E8 was evaluated in transgenic mice. The structure of the DC8E8 epitope was determined by X-ray crystallography. Results: Screening of a panel of monoclonal antibodies for their inhibitory activity in an in vitro pathological tau–tau interaction assay yielded DC8E8, which reduced the amount of oligomeric tau by 84%. DC8E8 recognised all developmental stages of tau pathology in AD human brains, including pretangles and intra- and extracellular tangles. Treatment with DC8E8 in a mouse AD model expressing mis-disordered human tau significantly reduced the amount of insoluble oligomerised tau and the number of early and mature neurofibrillary tangles in the transgenic mouse brains. By using a panel of tau-derived peptides in a competitive enzyme-linked immunosorbent assay, we identified the tau domain essential for pathological tau–tau interaction, which is targeted by DC8E8. The antibody was capable of binding to four highly homologous and yet independent binding regions on tau, each of which is a separate epitope. The X-ray structure of the DC8E8 Fab apo form, solved at 3.0 Å, suggested that the four DC8E8 epitopes form protruding structures on the tau molecule. Finally, by kinetic measurements with surface plasmon resonance, we determined that antibody DC8E8 is highly discriminatory between pathological and physiological tau. Conclusions: We have discovered defined determinants on mis-disordered truncated tau protein which are responsible for tau oligomerisation leading to neurofibrillary degeneration. Antibody DC8E8 reactive with these determinants is able to inhibit tau–tau interaction in vitro and in vivo. DC8E8 is able to discriminate between the healthy and diseased tau proteome, making its epitopes suitable targets, and DC8E8 a suitable candidate molecule, for AD immunotherapy.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The epitope for development of the tau vaccine AADvac1 was selected on the basis of in vitro experiments using a monoclonal antibody, DC8E8, which prevents tau oligomerization.
“The epitope for development of the tau vaccine AADvac1 was selected on the basis of in vitro experiments using a monoclonal antibody, DC8E8, which prevents tau oligomerization240.”
From Tau-targeting therapies for Alzheimer disease (2018) · cites this paper as [240]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. D. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 27,510 · see citing works
<i>Phaser</i> crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · see citing works
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463 · see citing works
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · see citing works
<i>MolProbity</i> : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115 · see citing works
Overview of the <i>CCP</i> 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353 · see citing works
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359 · see citing works
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,385 · see citing works
The global prevalence of dementia: a systematic review and metaanalysis.
Prince, M., Bryce, R., Albanese, E., Wimo, A., Ribeiro, W., & Ferri, C. P. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.11.007 · Cited by 4,941 · see citing works
Grundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676 · see citing works
Atomic structures of amyloid cross-β spines reveal varied steric zippers
Sawaya, M. R., Sambashivan, S., Nelson, R. A., Ivanova, M. I., Sievers, S. A., Apostol, M. I., Thompson, M. J., Balbirnie, M., Wiltzius, J. J. W., McFarlane, H. T., et al. (2007) · Nature · doi:10.1038/nature05695 · Cited by 2,279 · see citing works
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · see citing works
Nelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 2× · see citing works
“It has been shown that diseased modified tau proteins play an essential role in the clinical manifestation of AD [7,9,56].”
BackgroundAn introduction to data reduction: space-group determination, scaling and intensity statistics
Evans, P. R. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s090744491003982x · Cited by 1,507 · see citing works
Tau is a candidate gene for chromosome 17 frontotemporal dementia
Poorkaj, P., Bird, T. D., Wijsman, E., Nemens, E., Garruto, R. M., Anderson, L., Andreadis, A., Wiederholt, W. C., Raskind, M., & Schellenberg, G. D. (1998) · Annals of Neurology · doi:10.1002/ana.410430617 · Cited by 1,374 · see citing works
Alzheimer’s disease: Clinical trials and drug development
Mangialasche, F., Solomon, A., Winblad, B., Mecocci, P., & Kivipelto, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70119-8 · Cited by 1,217 · see citing works
Cairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · see citing works
von Bergen, M., Friedhoff, P., Biernat, J., Heberle, J., Mandelkow, E.-M., & Mandelkow, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.10.5129 · Cited by 1,021 · see citing works
Murray, M. E., Graff-Radford, N. R., Ross, O. A., Petersen, R. C., Duara, R., & Dickson, D. W. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70156-9 · Cited by 972 · see citing works
The pathological process underlying Alzheimer’s disease in individuals under thirty
Braak, H., & Del Tredici, K. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0789-4 · Cited by 812 · see citing works
Braak, F., Braak, H., & Mandelkow, E. (1994) · Acta Neuropathologica · doi:10.1007/bf00293315 · Cited by 769 · see citing works
Allen, B., Ingram, E., Takao, M., Smith, M. J., Jakes, R., Virdee, K., Yoshida, H., Holzer, M., Craxton, M., Emson, P. C., et al. (2002) · Journal of Neuroscience · doi:10.1523/jneurosci.22-21-09340.2002 · Cited by 746 · see citing works
Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges
Williams, D. R., & Lees, A. J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70042-0 · Cited by 650 · see citing works
Yanamandra, K., Kfoury, N., Jiang, H., Mahan, T. E., Ma, S., Maloney, S. E., Wozniak, D. F., Diamond, M. I., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.07.046 · Cited by 574 · see citing works
Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress.
Yan, S. D., Chen, X., Schmidt, A. M., Brett, J., Godman, G., Zou, Y. S., Scott, C. W., Caputo, C., Frappier, T., & Smith, M. A. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.16.7787 · Cited by 565 · see citing works
Asuni, A. A., Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2361-07.2007 · Cited by 506 · see citing works
Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17: A New Group of Tauopathies
Spillantini, M. G., Bird, T. D., & Ghetti, B. F. (1998) · Brain Pathology · doi:10.1111/j.1750-3639.1998.tb00162.x · Cited by 475 · see citing works
Sloane, P. D., Zimmerman, S. I., Suchindran, C., Reed, P. S., Wang, L., Boustani, M. A., & Sudha, S. (2002) · Annual Review of Public Health · doi:10.1146/annurev.publhealth.23.100901.140525 · Cited by 461 · see citing works
Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP
Josephs, K. A., Petersen, R. C., Knopman, D. S., Boeve, B. F., Whitwell, J. L., Duffy, J. R., Parisi, J. E., & Dickson, D. W. (2006) · Neurology · doi:10.1212/01.wnl.0000191307.69661.c3 · Cited by 455 · see citing works
Global Hairpin Folding of Tau in Solution
Jeganathan, S., von Bergen, M., Brutlach, H., Steinhoff, H.-J., & Mandelkow, E. (2006) · Biochemistry · doi:10.1021/bi0521543 · Cited by 432 · see citing works
Novak, M., Kabat, J., & Wischik, C. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05665.x · Cited by 398 · see citing works
MRI correlates of neurofibrillary tangle pathology at autopsy: A voxel-based morphometry study
Whitwell, J. L., Josephs, K. A., Murray, M. E., Kantarci, K., Przybelski, S. A., Weigand, S. D., Vemuri, P., Senjem, M. L., Parisi, J. E., Knopman, D. S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000324924.91351.7d · Cited by 376 · see citing works
Wang, J.-Z., Grundke-Iqbal, I., & Iqbal, K. (1996) · Nature Medicine · doi:10.1038/nm0896-871 · Cited by 360 · see citing works
Analysis of microtubule-associated protein tau glycation in paired helical filaments.
Ledesma, M. D., Bonay, P., Colaço, C., & Avila, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31849-5 · Cited by 333 · cited 1× · see citing works
“It is important to note, however, that posttranslational modifications of tau protein, such as truncation [37,69,70], abnormal hyperphosphorylation [71], glycosylation [72], glycation [73,74], ubiquitination [75], polyamination [76] and nitration [77], play key roles in tangle development.”
BackgroundBoutajangout, A., Ingadottir, J., Davies, P., & Sigurdsson, E. M. (2011) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07337.x · Cited by 306 · see citing works
Drug repositioning for Alzheimer's disease
Corbett, A., Pickett, J., Burns, A. S., Corcoran, J. P. T., Dunnett, S. B., Edison, P., Hagan, J. J., Holmes, C., Jones, E., Katona, C., et al. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3869 · Cited by 302 · see citing works
Immunotherapy Targeting Pathological Tau Prevents Cognitive Decline in a New Tangle Mouse Model
Boutajangout, A., Quartermain, D., & Sigurdsson, E. M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4363-10.2010 · Cited by 272 · see citing works
Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology
Schönheit, B., Zarski, R., & Ohm, T. G. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2003.09.009 · Cited by 262 · see citing works
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259 · cited 1× · see citing works
“Several independent studies have shown that either active or passive immunotherapy could prevent tau aggregation or clear tau aggregates and reduce tau hyperphosphorylation [22-24,26,59-62].”
BackgroundNakamura, K., Greenwood, A., Binder, L. I., Bigio, E. H., Denial, S., Nicholson, L. K., Zhou, X. Z., & Lu, K. P. (2012) · Cell · doi:10.1016/j.cell.2012.02.016 · Cited by 255 · see citing works
Žilka, N., Filipčík, P., Koson, P., Fialová, Ľ., Škrabana, R., Žilková, M., Rolkova, G., Kontseková, E., & Novák, M. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.05.029 · Cited by 254 · see citing works
Nitration of Tau Protein Is Linked to Neurodegeneration in Tauopathies
Horiguchi, T., Uryu, K., Giasson, B. I., Ischiropoulos, H., Lightfoot, R. T., Bellmann, C., Richter‐Landsberg, C., Lee, V. M. ‐., & Trojanowski, J. Q. (2003) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63462-1 · Cited by 220 · see citing works
Novak, M., Jakes, R., Edwards, P. C., Milstein, C., & Wischik, C. (1991) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.88.13.5837 · Cited by 217 · see citing works
Self-citationZommer, N., Sergeant, N., Schraen-Maschke, S., Blum, D., & Buee, L. (2012) · Current Alzheimer Research · doi:10.2174/156720512800492503 · Cited by 193 · see citing works
Efficacy and safety of immunization with phosphorylated tau against neurofibrillary tangles in mice
Boimel, M., Grigoriadis, N., Lourbopoulos, A., Haber, E., Abramsky, O., & Rosenmann, H. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2010.05.010 · Cited by 174 · see citing works
Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153 · see citing works
Kouri, N., Murray, M. E., Hassan, A., Rademakers, R., Uitti, R. J., Boeve, B. F., Graff‐Radford, N. R., Wszołek, Z. K., Litvan, I., Josephs, K. A., et al. (2011) · Brain · doi:10.1093/brain/awr234 · Cited by 133 · see citing works
Tau‐targeted treatment strategies in Alzheimer's disease
Götz, J., Ittner, A., & Ittner, L. M. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01713.x · Cited by 127 · see citing works
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works
Phosphorylated tau and the neurodegenerative foldopathies
Kosik, K. S., & Shimura, H. (2004) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2004.10.011 · Cited by 123 · see citing works
Bondareff, W., Wischik, C. M., Novák, M., Amos, W. B., Klug, A., & Roth, M. (1990) · Europe PMC (PubMed Central) · Cited by 121 · see citing works
Analysis of Tau Phosphorylation and Truncation in a Mouse Model of Human Tauopathy
Delobel, P., Lavenir, I., Fraser, G. M., Ingram, E., Holzer, M., Ghetti, B. F., Spillantini, M. G., Crowther, R. A., & Goedert, M. (2007) · American Journal Of Pathology · doi:10.2353/ajpath.2008.070627 · Cited by 120 · see citing works
Bancher, C., & Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00296494 · Cited by 115 · see citing works
Rat tau proteome consists of six tau isoforms: implication for animal models of human tauopathies
Hanes, J., Zilka, N., Bartkova, M., Caletkova, M., Dobrota, D., & Novak, M. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.05869.x · Cited by 109 · see citing works
Yamada, M. (2003) · Neuropathology · doi:10.1046/j.1440-1789.2003.00522.x · Cited by 99 · see citing works
Tucholski, J., Kuret, J., & Johnson, G. V. W. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.01871.x · Cited by 90 · see citing works
Tolnay, M., Sergeant, N., Ghestem, A., Chalbot, S., de Vos, R. A., Jansen Steur, E. N., Probst, A., & Delacourte, A. (2002) · Acta Neuropathologica · doi:10.1007/s00401-002-0591-z · Cited by 89 · see citing works
Truncated tau protein as a new marker for Alzheimer's disease.
Novák, M. (1994) · PubMed · Cited by 87 · see citing works
First transgenic rat model developing progressive cortical neurofibrillary tangles
Filipčík, P., Žilka, N., Bugos, O., Kučerák, J., Koson, P., Novák, P., & Novák, M. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.10.015 · Cited by 84 · see citing works
Koson, P., Žilka, N., Kováč, A., Kováčech, B., Korenova, M., Filipčík, P., & Novák, M. (2008) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2008.06329.x · Cited by 75 · see citing works
Tau pathology in children and young adults: can you still be unconditionally baptist?
Duyckaerts, C. J. (2011) · Acta Neuropathologica · doi:10.1007/s00401-010-0794-7 · Cited by 68 · see citing works
How a T Cell Receptor-like Antibody Recognizes Major Histocompatibility Complex-bound Peptide
Mareeva, T., Martı́nez-Hackert, E., & Sykulev, Y. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804996200 · Cited by 55 · see citing works
Transition of Tau Protein from Disordered to Misordered in Alzheimer’s Disease
Kovačech, B., Škrabana, R., & Novák, M. (2010) · Neurodegenerative Diseases · doi:10.1159/000283478 · Cited by 51 · see citing works
The self-perpetuating tau truncation circle
Žilka, N., Kováčech, B., Baráth, P., Kontseková, E., & Novák, M. (2012) · Biochemical Society Transactions · doi:10.1042/bst20120015 · Cited by 50 · see citing works
Folding of Alzheimer's core PHF subunit revealed by monoclonal antibody 423
Škrabana, R., KONTSEK, P., Mederlyova, A., Iqbal, K., & Novák, M. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.04.098 · Cited by 46 · see citing works
Žilková, M., Žilka, N., Kováč, A., Kováčech, B., Škrabana, R., Skrabanova, M., & Novák, M. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-101434 · Cited by 45 · see citing works
Žilka, N., Korenova, M., & Novák, M. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0499-y · Cited by 45 · see citing works
Anti-tau oligomers passive vaccination for the treatment of Alzheimer disease
Kayed, R. (2010) · Human Vaccines · doi:10.4161/hv.6.11.12689 · Cited by 38 · see citing works
Žilka, N., Kontseková, E., & Novák, M. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-15203 · Cited by 31 · see citing works
DC11: a novel monoclonal antibody revealing Alzheimer’s disease-specific tau epitope
Vechterova, L., Kontseková, E., Žilka, N., Ferencĭk, M., Ravid, R., & Novák, M. (2003) · Neuroreport · doi:10.1097/00001756-200301200-00017 · Cited by 31 · see citing works
Current strategies for the treatment of Alzheimer’s disease and other tauopathies
Dickey, C. A., & Petrucelli, L. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.5.665 · Cited by 24 · see citing works
The effect of postfusion cell density on establishment of hybridomas.
Kontseková, E., Novák, M., KONTSEK, P., Borecky, L., & Lesso, J. (1988) · PubMed · Cited by 19 · see citing works
Protein Truncation as a Common Denominator of Human Neurodegenerative Foldopathies
Jadhav, S., Žilka, N., & Novák, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8440-8 · Cited by 15 · see citing works
Disentangling Alzheimer's disease
Duyckaerts, C. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70171-5 · Cited by 12 · see citing works
Cehlár, O., Škrabana, R., Kováč, A., Kováčech, B., & Novák, M. (2012) · Acta Crystallographica Section F Structural Biology and Crystallization Communications · doi:10.1107/s1744309112030382 · Cited by 11 · see citing works
Richter, M., Hoffmann, R., & Singer, D. L. (2013) · Journal of Peptide Science · doi:10.1002/psc.2518 · Cited by 9 · see citing works
Macikova, I., Dedek, L., Vrzal, V., Kontseková, E., KONTSEK, P., ČIAMPOR, F. J., & Novák, M. (1992) · PubMed · Cited by 6 · see citing works
Myszka, D. G. (1999) · Journal of Molecular Recognition · doi:10.1002/(sici)1099-1352(199909/10)12:5
Flagged first, then by citations
1 of the 79 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tau-targeting therapies for Alzheimer disease
Congdon, E. E., & Sigurdsson, E. M. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0013-z · Cited by 1,113 · see citing works
Peptide-Based Vaccines: Current Progress and Future Challenges
Malonis, R. J., Lai, J. R., & Vergnolle, O. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00472 · Cited by 602 · see citing works
Novák, P., Schmidt, R., Kontseková, E., Žilka, N., Kováčech, B., Škrabana, R., Kazmerova, Z., Katina, S., Fialová, Ľ., Prčina, M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 306 · see citing works
A walk through tau therapeutic strategies
Jadhav, S., Ávila, J., Schöll, M., Kovács, G. G., Kövari, E., Škrabana, R., Evans, L., Kontseková, E., Malawska, B., de Silva, R., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0664-z · Cited by 286 · see citing works
Jouanne, M., Rault, S., & Voisin‐Chiret, A. S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.070 · Cited by 252 · see citing works
Kontseková, E., Žilka, N., Kováčech, B., Novák, P., & Novák, M. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt278 · Cited by 248 · see citing works
Tau Proteins and Tauopathies in Alzheimer’s Disease
Chong, F. P., Ng, K. Y., Koh, R. Y., & Chye, S. M. (2018) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-017-0574-1 · Cited by 248 · see citing works
Tau immunotherapy for Alzheimer's disease
Pedersen, J. T., & Sigurdsson, E. M. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.03.003 · Cited by 247 · see citing works
Tau local structure shields an amyloid-forming motif and controls aggregation propensity
Chen, D., Drombosky, K. W., Hou, Z., Sari, L., Kashmer, O. M., Ryder, B. D., Perez, V. A., Woodard, D. R., Lin, M. M., Diamond, M. I., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10355-1 · Cited by 196 · see citing works
Novak, P., Kovacech, B., Katina, S., Schmidt, R., Scheltens, P., Kontsekova, E., Ropele, S., Fialova, L., Kramberger, M., Paulenka-Ivanovova, N., et al. (2021) · Nature Aging · doi:10.1038/s43587-021-00070-2 · Cited by 187 · see citing works
Tau Biology and Tau-Directed Therapies for Alzheimer’s Disease
Bakota, L., & Brandt, R. (2016) · Drugs · doi:10.1007/s40265-015-0529-0 · Cited by 170 · see citing works
Passive immunotherapies targeting Aβ and tau in Alzheimer's disease
Plotkin, S. S., & Cashman, N. R. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105010 · Cited by 156 · see citing works
Novak, P., Schmidt, R., Kontsekova, E., Kovacech, B., Smolek, T., Katina, S., Fialova, L., Prcina, M., Parrak, V., Dal-Bianco, P., et al. (2018) · Alzheimer's Research & Therapy · doi:10.1186/s13195-018-0436-1 · Cited by 147 · see citing works
Novák, P., Žilka, N., Žilková, M., Kováčech, B., Škrabana, R., Ondrus, M., Fialová, L., Kontseková, E., Otto, M., & Novák, M. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2018.45 · Cited by 115 · see citing works
Tau-Based Therapeutics for Alzheimer’s Disease: Active and Passive Immunotherapy
Panza, F., Solfrizzi, V., Seripa, D., Imbimbo, B. P., Lozupone, M., Santamato, A., Tortelli, R., Galizia, I., Prete, C., Daniele, A., et al. (2016) · Immunotherapy · doi:10.2217/imt-2016-0019 · Cited by 105 · see citing works
Targeting tau: clinical trials and novel therapeutic approaches
VandeVrede, L., Boxer, A. L., & Polydoro, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134919 · Cited by 90 · see citing works
Modulation of Brain Hyperexcitability: Potential New Therapeutic Approaches in Alzheimer’s Disease
Toniolo, S., Sen, A., & Husain, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239318 · Cited by 94 · see citing works
Femtomolar Detection of Tau Proteins in Undiluted Plasma Using Surface Plasmon Resonance
Kim, S., Wark, A. W., & Lee, H. J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b01825 · Cited by 93 · see citing works
Immunotherapies for Aging-Related Neurodegenerative Diseases—Emerging Perspectives and New Targets
Kwon, S., Iba, M., Kim, C., & Masliah, E. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00853-2 · Cited by 92 · see citing works
Ten Years of Tau-Targeted Immunotherapy: The Path Walked and the Roads Ahead
Novak, P., Kontsekova, E., Zilka, N., & Novak, M. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00798 · Cited by 87 · see citing works
Smolek, T., Maďari, A., Farbáková, J., Kandrac, O., Jadhav, S., Cente, M., Brezováková, V., Novák, M., & Žilka, N. (2015) · The Journal of Comparative Neurology · doi:10.1002/cne.23877 · Cited by 74 · see citing works
Melková, K., Zapletal, V., Narasimhan, S., Jansen, S., Hritz, J., Škrabana, R., Zweckstetter, M., Jensen, M. R., Blackledge, M. J., & Žı́dek, L. (2019) · Biomolecules · doi:10.3390/biom9030105 · Cited by 72 · see citing works
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 57 · see citing works
A dip-and-read optical aptasensor for detection of tau protein
Ziu, I., Laryea, E. T., Alashkar, F., Wu, C. G., & Martić, S. (2020) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-02350-8 · Cited by 58 · see citing works
Progress in Target Drug Molecules for Alzheimer's Disease
Xie, J., Liang, R., Wang, Y., Huang, J., Cao, X., & Niu, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666191203113745 · Cited by 57 · see citing works
Weisová, P., Cehlár, O., Škrabana, R., Žilková, M., Filipčík, P., Kováčech, B., Prčina, M., Wojčiaková, Ľ., Fialová, Ľ., Smolek, T., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0770-y · Cited by 52 · see citing works
Four-Repeat Tauopathies: Current Management and Future Treatments
VandeVrede, L. A., Ljubenkov, P. A., Rojas, J. C., Welch, A. E., & Boxer, A. L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00888-5 · Cited by 53 · see citing works
Tau-directed approaches for the treatment of Alzheimer’s disease: focus on leuco-methylthioninium
Seripa, D., Solfrizzi, V., Imbimbo, B. P., Daniele, A., Santamato, A., Lozupone, M., Zuliani, G., Greco, A., Logroscino, G., & Panza, F. (2016) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2016.1140039 · Cited by 50 · see citing works
Alzheimer's disease vaccine development: A new strategy focusing on immune modulation
Marciani, D. J. (2015) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2015.08.008 · Cited by 46 · see citing works
Katsinelos, T., Tuck, B. J., Mukadam, A. S., & McEwan, W. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01139 · Cited by 44 · see citing works
Recent advancements toward therapeutic vaccines against Alzheimer’s disease
Herline, K., Drummond, E., & Wısnıewskı, T. (2018) · Expert Review of Vaccines · doi:10.1080/14760584.2018.1500905 · Cited by 44 · see citing works
siRNA drug delivery across the blood–brain barrier in Alzheimer's disease
Sajid, M. I., Sheikh, F. S., Anis, F., Nasim, N., Sumbria, R. K., Nauli, S. M., & Tiwari, R. K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114968 · Cited by 45 · see citing works
Corsetti, V., Borreca, A., Latina, V., Giacovazzo, G., Pignataro, A., Krashia, P., Natale, F., Cocco, S., Rinaudo, M., Malerba, F., et al. (2020) · Brain Communications · doi:10.1093/braincomms/fcaa039 · Cited by 41 · see citing works
Passive Immunotherapies Targeting Amyloid Beta and Tau Oligomers in Alzheimer’s Disease
Zanden, C. M. V., & Chi, E. Y. (2019) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2019.10.024 · Cited by 40 · see citing works
Congdon, E. E., Jiang, Y., & Sigurdsson, E. M. (2021) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2021.12.002 · Cited by 37 · see citing works
Liu, N., Liang, X., Chen, Y., & Xie, L. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102199 · Cited by 41 · see citing works
Truncated tau deregulates synaptic markers in rat model for human tauopathy
Jadhav, S., Katina, S., Kováč, A., Kazmerova, Z., Novák, M., & Žilka, N. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00024 · Cited by 39 · see citing works
Anti-dementia medications: current prescriptions in clinical practice and new agents in progress
Stella, F., Radanovic, M., Canineu, P. R., de Paula, V. D. J. R., & Forlenza, O. V. (2015) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098615592116 · Cited by 38 · see citing works
Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain
Detrez, J. R., Maurin, H., Van Kolen, K., Willems, R., Colombelli, J., Lechat, B., Roucourt, B., Van Leuven, F., Baatout, S., Larsen, P., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.03.010 · Cited by 39 · see citing works
Ji, M., Xie, X.-X., Liu, D., Yu, X., Zhang, Y., Zhang, L. L., Wang, S., Huang, Y., & Liu, R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0378-7 · Cited by 38 · see citing works
Bağcı, E., Akbaba, E., Mihăşan, M., Maniu, C. L., & Hriţcu, L. (2015) · Flavour and Fragrance Journal · doi:10.1002/ffj.3289 · Cited by 40 · see citing works
Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation
Novák, P., Cehlár, O., Škrabana, R., & Novák, M. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179942 · Cited by 36 · see citing works
Cognizance of posttranslational modifications in vaccines: A way to enhanced immunogenicity
Ojha, R., & Prajapati, V. (2021) · Journal of Cellular Physiology · doi:10.1002/jcp.30483 · Cited by 35 · see citing works
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation
Žilková, M., Nölle, A., Kováčech, B., Kontseková, E., Weisová, P., Filipčík, P., Škrabana, R., Prčina, M., Hromádka, T., Cehlár, O., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00948-z · Cited by 35 · see citing works
Carroll, T., Guha, S. K., Nehrke, K. W., & Johnson, G. V. W. (2021) · Biology · doi:10.3390/biology10101047 · Cited by 35 · see citing works
Congdon, E. E., Pan, R., Jiang, Y., Sandusky‐Beltran, L. A., Dodge, A., Lin, Y., Liu, M., Kuo, M., Kong, X., & Sigurdsson, E. M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104249 · Cited by 32 · see citing works
Tau immunization: a cautionary tale?
Mably, A. J., Kanmert, D., Donald, J. M. M., Liu, W., Caldarone, B. J., Lemere, C. A., O’Nuallain, B., Kosik, K. S., & Walsh, D. M. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.11.022 · Cited by 31 · see citing works
Spencer, B. J., Brüschweiler, S., Sealey‐Cardona, M., Rockenstein, E. M., Adame, A., Florio, J. B., Mante, M., Trinh, I., Rissman, R. A., Konrat, R., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1869-0 · Cited by 28 · see citing works
Joly‐Amado, A., Davtyan, H., Serraneau, K. S., Jules, P., Zitnyar, A., Pressman, E., Zagorski, K., Antonyan, T., Hovakimyan, A., Paek, H., et al. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104636 · Cited by 29 · see citing works
Emerging Developments in Targeting Proteotoxicity in Neurodegenerative Diseases
McAlary, L., Plotkin, S. S., & Cashman, N. R. (2019) · CNS Drugs · doi:10.1007/s40263-019-00657-9 · Cited by 25 · see citing works
Peptide-Based Vaccines for Neurodegenerative Diseases: Recent Endeavors and Future Perspectives
Vassilakopoulou, V., Karachaliou, C., Evangelou, A., Zikos, C. C., & Livaniou, E. (2021) · Vaccines · doi:10.3390/vaccines9111278 · Cited by 26 · see citing works
Ma, B., Zhao, J., & Nussinov, R. (2016) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2016.05.040 · Cited by 26 · see citing works
“Tau immunotherapy: Hopes and hindrances”
Shahpasand, K., Shamloo, A. S., Nabavi, S. M., Lu, K. P., & Zhou, X. Z. (2017) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1393594 · Cited by 24 · see citing works
Current peptide vaccine and immunotherapy approaches against Alzheimer’s disease
Parrocha, C. M. T., & Nowick, J. S. (2023) · Peptide Science · doi:10.1002/pep2.24289 · Cited by 24 · see citing works
Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 24 · see citing works
Capillary electrophoresis in the analysis of therapeutic peptides—A review
Štefánik, O., Majerová, P., Kováč, A., Mikuš, P., & Piešťanský, J. (2023) · Electrophoresis · doi:10.1002/elps.202300141 · Cited by 20 · see citing works
Apetri, A. C., Crespo, R., Juraszek, J., Pascual, G., Janson, R., Zhu, X., Zhang, H., Keogh, E. A., Holland, T., Wadia, J., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0543-z · Cited by 21 · see citing works
Shoeibi, A., Olfati, N., & Litvan, I. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1460356 · Cited by 22 · see citing works
Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder
Hamid, F. A. A. A., Marker, C. L., Raleigh, M. D., Khaimraj, A., Winston, S., Pentel, P. R., & Pravetoni, M. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.03.053 · Cited by 20 · see citing works
Tauopathies: Mechanisms and Therapeutic Strategies
Tan, C., Zhang, X.-Y., Tan, L., & Yu, J. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170187 · Cited by 20 · see citing works
Disease-modifying therapies for tauopathies: agents in the pipeline
Panza, F., Imbimbo, B. P., Lozupone, M., Greco, A., Seripa, D., Logroscino, G., Daniele, A., & Colosimo, C. (2019) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2019.1606715 · Cited by 19 · see citing works
Ghaffari, M. S., Sanadgol, N., & Abdollahi, M. R. (2020) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557520666200513122357 · Cited by 20 · see citing works
Helboe, L., Rosenqvist, N., Volbracht, C., Pedersen, L. Ø., Pedersen, J. T., Christensen, S., Egebjerg, J., Christoffersen, C. T., Bang‐Andersen, B., Beach, T. G., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220125 · Cited by 20 · see citing works
Targets, trials and tribulations in Alzheimer therapeutics
Gharat, R., Dixit, G., Khambete, M., & Prabhu, A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176230 · Cited by 18 · see citing works
Human Truncated Tau Induces Mature Neurofibrillary Pathology in a Mouse Model of Human Tauopathy
Zimova, I., Brezováková, V., Hromádka, T., Weisová, P., Cubinkova, V., Valachova, B., Filipčík, P., Jadhav, S., Smolek, T., Novák, M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160347 · Cited by 19 · see citing works
Kováčech, B., Fialová, Ľ., Filipčík, P., Škrabana, R., Žilková, M., Ivanovova, N. P., Kováč, A., Palova, D., Rolkova, G., Tomkova, K., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103818 · Cited by 19 · see citing works
Li, L., Miao, J., Chu, D., Jin, N., Tung, Y. C., Dai, C., Hu, W. H., Gong, C., Iqbal, K., & Liu, F. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13970 · Cited by 17 · see citing works
Davidson, R., Krider, R. I., Borsellino, P., Noorda, K., Alhwayek, G., & Vida, T. A. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45110553 · Cited by 17 · see citing works
Spreading of Pathology in Alzheimer’s Disease
Lv, Z., Tan, C., Yu, J., & Tan, L. (2017) · Neurotoxicity Research · doi:10.1007/s12640-017-9765-2 · Cited by 15 · see citing works
Bashir, M. A., Khan, A., Badshah, H., Filho, E. R., Din, Z. U., & Khan, A. (2019) · Drug Development Research · doi:10.1002/ddr.21537 · Cited by 15 · see citing works
Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration
Giunta, M., Solje, E., Gardoni, F., Borroni, B., & Benussi, A. (2021) · Journal of Experimental Pharmacology · doi:10.2147/jep.s262352 · Cited by 14 · see citing works
Benhamron, S., Rozenstein‐Tsalkovich, L., Nitzan, K., Abramsky, O., & Rosenmann, H. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.02.004 · Cited by 11 · see citing works
Development of an anti-tauopathy mucosal vaccine specifically targeting pathologic conformers
Tan, W., Thiruppathi, J., Hong, S. H., Puth, S., Pheng, S., Mun, B.-R., Choi, W., Lee, K., Park, H., Nguyen, D. T., et al. (2024) · npj Vaccines · doi:10.1038/s41541-024-00904-1 · Cited by 9 · see citing works
Sun, Y., Zhao, J. W., Lu, Y., Ngo, F. Y., Shuai, B., Zhang, Z., Feng, Y., & Rong, J. (2024) · Current Neuropharmacology · doi:10.2174/1570159x22666240515090434 · Cited by 8 · see citing works
Tau-based therapies for Alzheimer’s disease: Promising novel neuroprotective approaches
Sayas, C. L. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814037-6.00005-7 · Cited by 8 · see citing works
Untangling the tau microtubule-binding region
Toombs, J., & Zetterberg, H. (2020) · Brain · doi:10.1093/brain/awaa468 · Cited by 8 · see citing works
Karelina, T., Lerner, S., Stepanov, A. A., Meerson, M., & Demin, O. O. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12628 · Cited by 8 · see citing works
Li, Q., Xiong, C., Liu, H., Ge, H., Yao, X., & Liu, H. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.666043 · Cited by 8 · see citing works
Hsu, C.-H., Wang, S.-E., Lin, C.-L., Hsiao, C.-J., Sheu, S., & Wu, C. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/1939052 · Cited by 8 · see citing works
Bispecific Tau Antibodies with Additional Binding to C1q or Alpha-Synuclein
Quint, W. H., Matečko‐Burmann, I., Schilcher, I., Löffler, T., Schöll, M., Burmann, B. M., & Vogels, T. (2021) · Journal of Alzheimer s Disease · doi:10.3233/jad-201334 · Cited by 7 · see citing works
Active immunization in Alzheimer’s disease
Galasko, D. R. (2021) · Nature Aging · doi:10.1038/s43587-021-00076-w · Cited by 7 · see citing works
(2021) · Biointerface Research in Applied Chemistry · doi:10.33263/briac125.60326045 · Cited by 7 · see citing works
The engagement of microglia in tau-targeted immunotherapy in Alzheimer’s disease
Palova, D., Csokova, N. T., Markova, K., Kontseková, E., Kováčech, B., & Žilková, M. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021029 · Cited by 6 · see citing works
Meskova, K., Martonova, K., Hrasnova, P., Sinska, K., Skrabanova, M., Fialová, Ľ., Njemoga, S., Cehlár, O., Parmar, O., Kolenko, P., et al. (2023) · Antibodies · doi:10.3390/antib12030051 · Cited by 5 · see citing works
Wauters, E., Sleegers, K., Cruts, M., & Broeckhoven, C. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-805120-7.00009-9 · Cited by 5 · see citing works
Cehlár, O., Bagarova, O., Hornakova, L., & Škrabana, R. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021031 · Cited by 7 · see citing works
Development of an Effective Alzheimer’s Vaccine
Marciani, D. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809819-6.00011-3 · Cited by 4 · see citing works
Analysis of the Biomarkers for Neurodegenerative Diseases in Aged Progranulin Deficient Mice
Zhao, X., Hasan, S., Liou, B., Lin, Y., Sun, Y., & Liu, C.-J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020629 · Cited by 4 · see citing works
Primio, C. D., Quercioli, V., Siano, G., Kováčech, B., Novák, M., & Cattaneo, A. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/041756 · Cited by 4 · see citing works
Efficacy, Immunogenicity, Safety, and Tolerability of AADvac1 in Alzheimer Disease
da Silva, A. M. P., Falcão, L., Ribeiro, F. V., Menezes, I. R., Leite, M. G. H. S. J., de Farias, E. H., Nascimento, M. D. V., Corin, A. S., Quiroga, D. G., Franco, E. D. S., et al. (2025) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000686 · Cited by 2 · see citing works
TAU IMMUNOTHERAPY FOR ALZHEIMER’S (Review Article)
Chandrakumaran, A., Achuthaprasad, A., DANIEL, P., & JACOB, J. (2022) · EXPERIMENTAL & CLINICAL MEDICINE GEORGIA · doi:10.52340/jecm.2022.02.15 · Cited by 2 · see citing works
Noninfectious Disease Vaccines
El-Turabi, A., & Bachmann, M. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35761-6.00040-7 · Cited by 2 · see citing works
Frontotemporal lobar degeneration
Kim, B., Viera-Ortiz, A., Phan, J. M., Irwin, D. J., & Lee, E. B. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00041-1 · Cited by 2 · see citing works
Tau local structure shields amyloid motif and controls aggregation propensityPreprint
Chen, D., Drombosky, K. W., Hou, Z., Sari, L., Kashmer, O. M., Ryder, B. D., Perez, V. A., Woodard, D. R., Lin, M. M., Diamond, M. I., et al. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/330266 · Cited by 2 · see citing works
Kohli, A., Kothiyal, P., Guru, S., C., R., & Nagar, P. (2015) · International journal of pharma research and review · Cited by 1 · see citing works
Therapeutic Strategies in Neurodegenerative Diseases
Eid, A. M., Faridar, A., & Appel, S. H. (2024) · Springer eBooks · doi:10.1007/978-3-031-68237-7_39 · Cited by 1 · see citing works
Jellinger, K. A. (2015) · EMJ Neurology · doi:10.33590/emjneurol/10311025 · Cited by 1 · see citing works
The manifold works of Prof. Michal Novak
Novák, P., & Žilka, N. (2021) · General Physiology and Biophysics · doi:10.4149/gpb_2021045 · Cited by 1 · see citing works
Immunotherapy for the Treatment of Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00009-4
Potential of Blood- and CSF-Based Biomarkers for Alzheimer’s Disease Diagnostics
Goldwaser, E. L., & Nagele, R. G. (2020) · Oxford University Press eBooks · doi:10.1093/oso/9780190634230.003.0016
- Authors
- Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., & Novak, M.
- Venue
- Alzheimer's Research & Therapy
- Published
- 2014-08-01
- Volume
- 6
- Issue
- 4
- Pages
- 45-45
- ISSN
- 1758-9193 (ISSN-L)
- PMC
- PMC4255369
- OpenAlex
- W2147317695
- Cited by
- 112
- References
- 79
- Citations by year
- 2026: 5 · 2025: 3 · 2024: 5 · 2023: 6 · 2022: 10 · 2021: 14 · 2020: 13 · 2019: 15 · 2018: 14 · 2017: 8 · 2016: 9 · 2015: 8 · 2014: 2
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Alzheimer s Research & Therapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DORA PSI (Paul Scherrer Institute) (submittedVersion, other-oa)
- Funders
- European Commission (226716)
- Topics
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- tau protein, Alzheimer's disease, tau immunotherapy, neurofibrillary tangles, epitope mapping, truncated tau, tauopathy, drug target identification
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
